Spinal Cord Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida, or Friedreich’s ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head, or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet, or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.

The SCI pipeline drugs market research report provides comprehensive information on the therapeutics under development for SCI, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for SCI and features dormant and discontinued projects.

SCI Pipeline Drugs Market Segmentation by Targets

Some of the targets of the SCI pipeline drugs market are Receptor Type Tyrosine Protein Phosphatase S, Reticulon 4, Apoptosis Associated Speck Like Protein Containing A CARD, Free Radical, Glutamate Ionotropic Receptor AMPA Type Subunit, and Phospholipase A2.

SCI Pipeline Drugs Market Analysis, by Targets

SCI Pipeline Drugs Market Analysis, by Targets

For more SCI pipeline drugs market target insights, download a free report sample

SCI Pipeline Drugs Market Segmentation by Mechanism of Actions

Some of the mechanisms of action of the SCI pipeline drugs market are Receptor Type Tyrosine Protein Phosphatase S Inhibitor, Reticulon 4 Inhibitor, Apoptosis Associated Speck Like Protein Containing A CARD Inhibitor, Free Radical Scavenger, Glutamate Ionotropic Receptor AMPA Type Subunit Agonist, and Phospholipase A2 Inhibitor.

SCI Pipeline Drugs Market Analysis, by Mechanism of Actions

SCI Pipeline Drugs Market Analysis, by Mechanism of Actions

For more mechanism of action insights into the SCI pipeline drugs market, download a free report sample

SCI Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the SCI pipeline drugs market are intrathecal, intravenous, oral, parenteral, subcutaneous, and intracerebral.

SCI Pipeline Drugs Market Analysis, by Routes of Administration

SCI Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the SCI pipeline drugs market, download a free report sample

SCI Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the SCI pipeline drugs market are Cell Therapy, Small Molecule, Synthetic Peptide, Gene Therapy, Monoclonal Antibody, and Biologic.

SCI Pipeline Drugs Market Analysis, by Molecule Types

SCI Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the SCI pipeline drugs market, download a free report sample

Competitive Landscape

Some of the key companies in the SCI pipeline drugs market are NervGen Pharma Corp, AXONIS Therapeutics Inc, Axoltis Pharma SAS, Novoron Bioscience Inc, RespireRx Pharmaceuticals Inc, and SanBio Co Ltd.

SCI Pipeline Drugs Market Analysis, by Companies

SCI Pipeline Drugs Market Analysis, by Companies

To know more about the SCI pipeline drugs market companies, download a free report sample

SCI Pipeline Drugs Market Report Overview

Key Targets Receptor Type Tyrosine Protein Phosphatase S, Reticulon 4, Apoptosis Associated Speck Like Protein Containing A CARD, Free Radical, Glutamate Ionotropic Receptor AMPA Type Subunit, and Phospholipase A2
Key Mechanism of Actions Receptor Type Tyrosine Protein Phosphatase S Inhibitor, Reticulon 4 Inhibitor, Apoptosis Associated Speck Like Protein Containing A CARD Inhibitor, Free Radical Scavenger, Glutamate Ionotropic Receptor AMPA Type Subunit Agonist, and Phospholipase A2 Inhibitor
Key Routes of Administration Intrathecal, Intravenous, Oral, Parenteral, Subcutaneous, and Intracerebral
Key Molecule Types Cell Therapy, Small Molecule, Synthetic Peptide, Gene Therapy, Monoclonal Antibody, and Biologic
Key Companies NervGen Pharma Corp, AXONIS Therapeutics Inc, Axoltis Pharma SAS, Novoron Bioscience Inc, RespireRx Pharmaceuticals Inc, and SanBio Co Ltd

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of SCI.
  • Reviews of pipeline therapeutics for SCI by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Reviews key companies involved in SCI therapeutics and enlist all their major and minor projects.
  • Evaluation of SCI therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for SCI.

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for SCI.
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding the SCI pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

9 Meters Biopharma Inc
AbbVie Inc
AlaMab Therapeutics Inc
Angion Biomedica Corp
Aposcience AG
Asha Therapeutics LLC
AstraZeneca Plc
Athersys Inc
Axoltis Pharma SAS
Axoneural Therapeutics Inc
AXONIS Therapeutics Inc
BioAxone BioSciences Inc
Cellatoz Therapeutics Inc
CellCure
CSL Ltd
Daewoong Pharmaceutical Co Ltd
EUSOL Biotech Co Ltd
GABA Therapeutics Inc
Gene Therapy Research Institution Co Ltd
Genervon Biopharmaceuticals LLC
GNT Pharma Co Ltd
Helixmith Co Ltd
Hemostemix Inc
Hibernaid Inc
Histocell SL
Hope Biosciences LLC
Hopstem Biotechnology LLC
iCELL Biotechnology Co Ltd
Jazz Pharmaceuticals Plc
Kidswell Bio Corp
Kringle Pharma Inc
Lineage Cell Therapeutics Inc
Locate Bio Ltd
Mapreg SAS
Mitsubishi Tanabe Pharma Corp
NervGen Pharma Corp
NeuExcell Therapeutics Inc
Neuroplast BV
New World Laboratories Inc
Novago Therapeutics AG
Novartis AG
Novoron Bioscience Inc
NuNerve Pty Ltd
Oligogen Inc
Palisade Bio, Inc
PharmatrophiX Inc
Q Therapeutics Inc
Q32 Bio Inc
Radikal Therapeutics Inc
RE-Stem Biotech Co Ltd
ReNetX Bio
RespireRx Pharmaceuticals Inc
Rudacure Co Ltd
S.Biomedics Co Ltd
SanBio Co Ltd
Shanghai Angecon Biotechnology Co Ltd
Stand Up Therapeutics Co Ltd
StemCyte Inc
Stemedica Cell Technologies Inc
Stemmatters Biotecnologia e Medicina Regenerativa SA
Sumitomo Pharma Co Ltd
TechnoPhage SA
Truvitech LLC
Tumorend LLC
VersaPeutics Inc
ZyVersa Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Spinal Cord Injury – Overview

Spinal Cord Injury – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Spinal Cord Injury – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Spinal Cord Injury – Companies Involved in Therapeutics Development

Spinal Cord Injury – Drug Profiles

Spinal Cord Injury – Dormant Projects

Spinal Cord Injury – Discontinued Products

Spinal Cord Injury – Product Development Milestones

Featured News & Press Releases

Sep 17, 2022: NervGen Pharma presenting at upcoming Military Health System Research Symposium and the 61st International Spinal Cord Society Annual Scientific Meeting

May 20, 2022: Birmingham research brings hope for spinal cord injury treatment

May 18, 2022: NervGen hosting ppanel discussion with leading experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA)

May 12, 2022: NervGen Pharma receives approval to proceed to the final dose cohort in phase 1 clinical trial of NVG-291

Mar 31, 2022: NervGen presenting interim phase 1 clinical trial data for NVG-291 at the 2022 American Academy of Neurology Annual Meeting

Mar 23, 2022: NervGen Pharma to present at 2022 virtual growth conference presented by Maxim Group

Mar 15, 2022: NervGen Pharma receives approval from Safety Review Committee to proceed to second cohort in multiple ascending dose portion of phase 1 clinical trial of NVG-291

Jan 10, 2022: NervGen Pharma announces intent to conduct groundbreaking spinal cord injury clinical trial in exclusive partnership with Shirley Ryan AbilityLab, 1-Ranked Hospital in Physical Medicine & Rehabilitation

Dec 22, 2021: NervGen Pharma receives ethics board approval for multiple ascending dose portion of NVG-291 phase 1 trial

Nov 04, 2021: NervGen presents additional phase 1 clinical trial data for NVG-291 at Neuroscience 2021 / safety review committee provides recommendation to proceed to multiple ascending dose portion of the trial

Oct 27, 2021: NervGen Pharma announces spinal cord injury clinical advisory board

Oct 18, 2021: NervGen presents interim phase 1 clinical trial data for NVG-291 at the American Neurological Association 146th Annual Meeting / NVG-291 demonstrated to be well tolerated along with a favorable pharmacokinetic profile

Sep 27, 2021: NervGen Pharma partners with Imeka to use novel neuroimaging technology in clinical trials

Sep 12, 2021: NervGen Pharma presenting at the H.C. Wainwright 23rd Annual Global Investment Conference

Sep 08, 2021: Phase 2 Trial of MT-3921 initiated for treatment of spinal cord injury

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Spinal Cord Injury, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Companies, 2022 (Contd..2)

Number of Products under Development by Companies, 2022 (Contd..3)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Spinal Cord Injury – Dormant Projects, 2022

Spinal Cord Injury – Dormant Projects, 2022 (Contd..1)

Spinal Cord Injury – Dormant Projects, 2022 (Contd..2)

Spinal Cord Injury – Dormant Projects, 2022 (Contd..3)

Spinal Cord Injury – Dormant Projects, 2022 (Contd..4)

Spinal Cord Injury – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Spinal Cord Injury, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Spinal Cord Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Spinal Cord Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Spinal Cord Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Spinal Cord Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.